CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 25, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that Alnylam and collaborators will present data from its Phase I trials with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection, at the 2006 Pediatric Academic Societies’ (PAS) Annual Meeting being held in San Francisco April 29 - May 2 at the Moscone West Convention Center.
